Craddock, C., Houlton, A., Ferguson, P., Raghavan, M., Fox, S., Dudley, L., . . . Vyas, P. (2016). Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. American Society of Hematology.
Style de citation Chicago (17e éd.)Craddock, C., et al. Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. American Society of Hematology, 2016.
Style de citation MLA (9e éd.)Craddock, C., et al. Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. American Society of Hematology, 2016.